Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ И С3-ГЛОМЕРУЛОПАТИЯ: ИТОГИ КОНФЕРЕНЦИИ «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) ПО СПОРНЫМ ВОПРОСАМ

https://doi.org/10.24884/1561-6274-2018-22-4-18-39

Полный текст:

Аннотация

Система комплемента играет ключевую роль в развитии таких заболеваний, как атипичный гемолитико-уремический синдром (аГУС) и С3-гломерулопатия (С3ГП). В данной публикации мы обобщаем итоги конференции «Kidney Disease: Improving Global Outcomes» (KDIGO)  2015 по спорным вопросам, в ходе которой экспертами были коллегиально приняты  ключевые подходы к ведению этих двух заболеваний. Были рассмотрены такие области, как  патоморфология почек, клинические фенотипы и клиническая оценка, генетические аспекты болезни, варианты  приобретенной болезни и терапевтические стратегии. С целью помощи клиницистам, которые наблюдают таких пациентов, подробно обсуждены и обоснованы рекомендации по  выбору оптимальной лечебной стратегии. Были выделены пробелы в знании и обозначена  стратегия приоритетных исследований с целью разрешения основных противоречий.

Об авторах

Тимоти Г. Дж. Гудшип
Институт Медицинской Генетики Университет Ньюкасла
Великобритания

Центал Парквэй, Ньюкасл-на-Тайне, NE1 3BZ, Великобритания

 



Г. Теренс Кук
Кампус Императорского Колледжа
Великобритания
Центр изучения комплемента и воспаления, Отделение медицины


Фади Фахури
Университетский госпитальный центр Нанта
Франция
INSERM, UMR-S 1064 (Центр исследований в трансплантации и иммунологии)  и Отделение Нефрологии и Иммунологии


Фернандо К. Фервенца
Клиника Mayo
Соединённые Штаты Америки
Отделение нефрологии и гипертензии


Вероник Фремо-Бакши
Государственный госпиталь Парижа Европейский госпиталь Жоржа Помпиду
Франция


Давид Каванаг
Институт Медицинской Генетики Университет Ньюкасла
Великобритания


Карла М. Нестер
Медицинский колледж Карвера, Университет Айовы
Соединённые Штаты Америки

Лаборатория молекулярной отоларингологии и исследований в нефрологии

Подразделение Нефрологии, Отделение внутренних болезней



Марина Норис
IRCCS – Институт фармакологических исследований «Марио Негри» Клинический исследовательский Институт редких заболеваний «Aldo e Cele Dacco»
Италия


Мэтью К. Пикеринг
Кампус Императорского Колледжа Хэммерсмита,
Великобритания
Центр изучения комплемента и воспаления, Отделение медицины


Сантьяго Родригес де Кордоба
Центр Биологических исследований, Национальный совет научных исследований Центр Биомедицинских исследований редких заболеваний
Испания


Лубка Т. Руменина
Национальный институт здоровья и медицинских исследований, объединенное исследовательское отделение S 1138, комплемент и болезни, францисканский исследовательский центр Парижский Университет Декарта в составе Сорбонны Университет Пьера и Мари Кюри (UPMC)
Франция


Санджив Сети
Клиника Mayo
Соединённые Штаты Америки
Отделение лабораторной медицины и патологии


Ричард Дж. Н. Смит
Медицинский колледж Карвера, Университет Айовы
Россия

Лаборатория молекулярной отоларингологии и исследований в нефрологии

Подразделение Нефрологии, Отделение внутренних болезней

200 Хоукинс Драйв – 21151 PFP, Айова Сити, Айова 52242, США



Список литературы

1. Chua JS, Baelde HJ, Zandbergen M et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 2015; 26: 2239–2247. doi: 10.1681/ASN.2014050429

2. Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079–1089. doi:10.1038/ki.2013.377

3. Hou J, Markowitz GS, Bomback AS et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014; 85: 450–456. doi: 10.1038/ki.2013.340

4. Larsen CP, Ambuzs JM, Bonsib SM et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014; 86: 154–161. doi: 10.1038/ki.2013.548

5. Larsen CP, Messias NC, Walker PD et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015; 88: 867–873. doi: 10.1038/ki.2015.195

6. Cook HT. C4d staining in the diagnosis of C3 glomerulopathy. J Am Soc Nephrol 2015; 26: 2609–2611. doi: 10.1681/ASN.2015040433

7. Sethi S, Nasr SH, De Vriese AS et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 2015; 26: 2852–2859. doi: 10.1681/ASN.2014040406

8. West CD, Witte DP, McAdams AJ. Composition of nephritic factorgenerated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001; 37: 1120–1130. doi: -

9. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465–473. doi: 10.1038/ki.2012.212

10. Sethi S, Gamez JD, Vrana JA et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952–960. doi: 10.1038/ki.2008.657

11. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15–39. doi: 10.1007/s00467-015-3076-8

12. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267–1279. doi: 10.1182/blood-2005-10-007252

13. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33: 508–530. doi: 10.1016/j.semnephrol.2013.08.003

14. Sansbury FH, Cordell HJ, Bingham C et al. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J Med Genet 2014;51:756–764. doi: 10.1136/jmedgenet-2014-102498

15. Bresin E, Rurali E, Caprioli J et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013; 24: 475– 486. doi: 10.1681/ASN.2012090884

16. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035–1050. doi: 10.1681/ASN.2004100861

17. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454–464. doi: 10.1038/ki.2012.63

18. Fervenza FC, Smith RJ, Sethi S. Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis 2012; 60: 126– 132. doi: 10.1053/j.ajkd.2012.03.007

19. Sandhu G, Bansal A, Ranade A et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis 2012; 60: 1039–1043. doi: 10.1053/j.ajkd.2012.04.032

20. Vernon KA, Goicoechea de Jorge E, Hall AE et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 2012; 60: 121–125. doi: 10.1053/j.ajkd.2012.02.329

21. Yu Y, Triebwasser MP, Wong EK et al. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet 2014; 23: 5283–5293. doi: 10.1093/hmg/ddu226

22. Kavanagh D, Yu Y, Schramm EC et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet 2015; 24: 3861–3870. doi: 10.1093/hmg/ddv091

23. Recalde S, Tortajada A, Subias M et al. Molecular Basis of Factor HR1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol 2016; 27: 1305–1311. doi: 10.1681/ASN.2015050580

24. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83: 18–34. doi: 10.1097/01.md.0000111061.69212.59

25. Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III. Retin Cases Brief Rep 2016; 10: 72–78. doi: 10.1097/ICB.0000000000000164

26. Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 1989; 73: 297–302. doi: -

27. Mathieson PW, Wurzner R, Oliveria DB et al. Complementmediated adipocyte lysis by nephritic factor sera. J Exp Med 1993;177: 1827–1831. doi: -

28. Fritsche LG, Chen W, Schu M et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013; 45: 433–439. doi: 10.1038/ng.2578

29. Gerber A, Karch H, Allerberger F et al. Clinical course and the role of shiga toxin- producing Escherichia coli infection in the hemolyticuremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186: 493–500. doi: 10.1086/341940

30. Angioi A, Fervenza FC, Sethi S et al. Diagnosis of complement alternative pathway disorders. Kidney Int 2016; 89: 278–288. doi: 10.1016/j.kint.2015.12.003

31. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643–657. doi: 10.1038/nrneph.2012.214

32. Bu F, Borsa NG, Jones MB et al. High-Throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 2016; 27: 1245–1253. doi: 10.1681/ASN.2015040385

33. de Cordoba SR. Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations. Immunobiology 2016; 221: 709–714. doi: 10.1016/j.imbio.2015.05.015

34. Noris M, Brioschi S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542–1547. doi: 10.1016/S0140-6736(03)14742-3

35. Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100: 12966–12971. doi: 10.1073/pnas.2135497100

36. Ault BH, Schmidt BZ, Fowler NL et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272: 25168–25175. doi: -

37. Levy M, Halbwachs-Mecarelli L, Gubler MC et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949–956. doi: -

38. Martinez-Barricarte R, Heurich M, Valdes-Canedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702–3712. doi: 10.1172/JCI43343

39. Montes T, Goicoechea de Jorge E, Ramos R et al. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 2008; 45: 2897–2904. doi: 10.1016/j.molimm.2008.01.027

40. Schejbel L, Schmidt IM, Kirchhoff M et al. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun 2011;12:90–99. doi: 10.1038/gene.2010.63

41. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009;114:4261–4271. doi: 10.1182/blood-2009-05-223834

42. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:345–357. doi: 10.1056/NEJMoa0810739

43. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554–562. doi: 10.2215/CJN.04760512

44. Lemaire M, Fremeaux-Bacchi V, Schaefer F et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531–536. doi: 10.1038/ng.2590

45. Maga TK, Nishimura CJ, Weaver AE et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31: E1445–E1460. doi: 10.1002/humu.21256

46. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676– 1687. doi: 10.1056/NEJMra0902814

47. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703–712. doi: 10.1093/hmg/ddi066

48. Challis RC, Araujo GS, Wong EK et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2016; 27: 1617– 1624. doi: 10.1681/ASN.2015010100

49. Chen Q, Wiesener M, Eberhardt HU et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 2014; 124: 145–155. doi: 10.1172/JCI71866

50. Gale DP, de Jorge EG, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794–801. doi: 10.1016/S0140-6736(10)60670-8

51. Tortajada A, Yebenes H, Abarrategui-Garrido C et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 2013; 123: 2434–2446. doi: 10.1172/JCI68280

52. Valoti E, Alberti M, Tortajada A et al. A novel atypical hemolytic uremic syndrome- associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H- dependent complement regulation. J Am Soc Nephrol 2015; 26: 209–219. doi: 10.1681/ASN.2013121339

53. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006; 3: e431. doi: 10.1371/journal.pmed.0030431

54. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436–1446. doi: 10.2215/CJN.09541010

55. Chauvet S, Roumenina LT, Bruneau S et al. A familial C3GN secondary to defective C3 regulation by complement receptor 1 and factor H. J Am Soc Nephrol 2016; 27: 1665–1677. doi: 10.1681/ASN.2015040348

56. Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22: 704–712. doi: 10.1097/MNH.0b013e328365b3fe

57. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424. doi: 10.1038/gim.2015.30

58. Frimat M, Tabarin F, Dimitrov JD et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013; 122: 282–292. doi: 10.1182/blood-2013-03-489245

59. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104: 240–245. doi: 10.1073/pnas.0603420103

60. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181–1190. doi: 10.1172/JCI16651

61. Marinozzi MC, Vergoz L, Rybkine T et al. Complement factor B mutations in atypical hemolytic uremic syndrome-diseaserelevant or benign? J Am Soc Nephrol 2014; 25: 2053– 2065. doi: 10.1681/ASN.2013070796

62. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715–1726. doi: 10.1182/blood-2014-02-558296

63. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68: 478–484. doi: 10.1086/318201

64. Roumenina LT, Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114: 2837–2845. doi: 10.1182/blood-2009-01-197640

65. Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71: 1285–1295. doi: 10.1086/344515

66. Schramm EC, Roumenina LT, Rybkine T et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 2015; 125: 2359–2369. doi: 10.1182/blood-2014-10-609073

67. Stahl AL, Vaziri-Sani F, Heinen S et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008; 111: 5307–5315. doi: 10.1182/blood-2007-08-106153

68. Bernabeu-Herrero ME, Jimenez-Alcazar M, Anter J et al. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015; 67: 276–286. doi: 10.1016/j.molimm.2015.06.021

69. Caprioli J, Castelletti F, Bucchioni S et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385– 3395. doi: 10.1093/hmg/ddg363

70. Harris CL, Heurich M, Rodriguez de Cordoba S et al. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012; 33: 513–521. doi: 10.1016/j.it.2012.06.001

71. Pickering MC, de Jorge EG, Martinez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249–1256. doi: 10.1084/jem.20070301

72. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844–1859. doi: 10.2215/CJN.02210310

73. Sanchez Chinchilla D, Pinto S, Hoppe B et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014; 9: 1611–1619. doi: 10.2215/CJN.01640214

74. Abrera-Abeleda MA, Nishimura C, Frees K et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551–1559. doi: 10.1681/ASN.2010080795

75. Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant 2016; 31: 717–725. doi: 10.1093/ndt/gfu317

76. Goicoechea de Jorge E, Caesar JJ, Malik TH et al. Dimerization of complement factor H- related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A 2013; 110: 4685–4690. doi: 10.1073/pnas.1219260110

77. Licht C, Heinen S, Jozsi M et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70: 42–50. doi: 10.1038/sj.ki.5000269

78. Wong EK, Anderson HE, Herbert AP et al. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014; 25: 2425–2433. doi: 10.1681/ASN.2013070732

79. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169–2181. doi: 10.1056/NEJMoa1208981

80. Mannucci PM, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thromb Res 2015; 136: 851–854. doi: 10.1016/j.thromres.2015.09.007

81. Donne RL, Abbs I, Barany P et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002; 40: E22. doi: 10.1053/ajkd.2002.36938

82. Povey H, Vundru R, Junglee N et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 2014; 82: 326–331. doi: 10.5414/CN107958

83. Tarshish P, Bernstein J, Tobin JN et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone–a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6: 123–130. doi: –

84. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87: 1061–1073. doi:

85. Coppo R, Bonaudo R, Peruzzi RL et al. Liver transplantation for aHUS: still needed in the eculizumab era? Pediatr Nephrol 2016; 31: 759–768. doi: 10.1038/ki.2014.423

86. Rabasco C, Cavero T, Roman E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015; 88: 1153–1160. doi: 10.1038/ki.2015.227

87. Besbas N, Gulhan B, Gucer S et al. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol 2014; 27: 457–460. doi: 10.1007/s40620-013- 0008-1

88. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748–756. doi: 10.2215/CJN.12901211

89. Bonucchi D, Leonelli M, Damiano F et al. [Post-transplant recurrence of glomerulonephritis: a complex clinical case]. G Ital Nefrol 2010; 27 Suppl 52:S82–S84. doi: –

90. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with densedeposit disease. N Engl J Med 2012; 366: 1161–1163. doi: 10.1056/NEJMc1112273

91. Garnier AS, Augusto JF, Pellier I et al. Successful longterm outcome of kidney transplantation in a patient with X-linked thrombocytopenia: 9-year follow-up. Transplantation 2014; 98: e57–e58. doi: 10.1097/TP.0000000000000338

92. Gurkan S, Fyfe B, Weiss L et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013; 28: 1975–1981. doi: 10.1007/s00467-013-2503-y

93. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229–1237. doi: 10.1681/ASN.2011121186

94. Inman M, Prater G, Fatima H et al. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 2015; 8: 445–448. doi: 10.1093/ckj/sfv044

95. Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3- dominant membranoproliferative glomerulopathy. Pediatr Nephrol 2013; 28: 2227–2231. doi: 10.1007/s00467-013-2565-x

96. Le Quintrec M, Lionet A, Kandel C et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 2015; 65: 484–489. doi: 10.1053/j.ajkd.2014.09.025

97. McCaughan JA, O’Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12: 1046–1051. doi: 10.1111/j.1600-6143.2011.03923.x

98. Oosterveld MJ, Garrelfs MR, Hoppe B et al. Eculizumab in pediatric Dense Deposit Disease. Clin J Am Soc Nephrol 2015; 10: 1773–1782. doi: 10.2215/CJN.01360215

99. Ozkaya O, Nalcacioglu H, Tekcan D et al. Eculizumab therapy in a patient with dense- deposit disease associated with partial lipodystropy. Pediatr Nephrol 2014; 29:1283–1287. doi: 10.1007/s00467-013-2748-5

100. Radhakrishnan S, Lunn A, Kirschfink M et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165–1166. doi: 10.1056/NEJMc1106619

101. Rousset-Rouviere C, Cailliez M, Garaix F et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014; 29: 1107–1111. doi: 10.1007/s00467-013-2711-5

102. Sanchez-Moreno A, De la Cerda F, Cabrera R et al. Eculizumab in dense deposit disease after renal transplantation. Pediatr Nephrol 2014; 29: 2055–2059. doi: 10.1007/s00467-014- 2839-y

103. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense deposit disease. N Engl J Med. 2012; 366: 1163–1165. doi: 10.1056/NEJMc1111953

104. Barbour SJ, Espino-Hernandez G, Reich HN et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016;89: 167–175. doi: 10.1038/ki.2015.322

105. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534–545. doi: 10.1038/ki.2009.243

106. Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546–556. doi: 10.1038/ki.2009.168

107. Amornsiripanitch N, Hong S, Campa MJ et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010;16: 3226–3231. doi: 10.1158/1078-0432.CCR-10-0321

108. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of antifactor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180– 2187. doi: 10.1681/ASN.2010030315

109. Khandelwal P, Gupta A, Sinha A et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 2015; 30: 451–457. doi: 10.1007/s00467-014-2948-7

110. Sinha A, Gulati A, Saini S et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014; 85: 1151–1160. doi: 10.1038/ki.2013.373

111. Sheerin NS, Kavanagh D, Goodship TH et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year’s experience. QJM 2016; 109: 27– 33. doi: 10.1093/qjmed/hcv082

112. Wetzels JF, van de Kar NC. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. Am J Kidney Dis 2015; 65: 342. doi: 10.1053/j.ajkd.2014.04.039

113. Ardissino G, Possenti I, Tel F et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015; 66: 172–173. doi: 10.1053/j.ajkd.2015.04.010

114. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64: 633–637. doi: 10.1053/j.ajkd.2014.01.434


Для цитирования:


Г. Дж. Гудшип Т., Кук Г., Фахури Ф., Фервенца Ф., Фремо-Бакши В., Каванаг Д., Нестер К.М., Норис М., Пикеринг М.К., де Кордоба С., Руменина Л.Т., Сети С., Дж. Н. Смит Р. АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ И С3-ГЛОМЕРУЛОПАТИЯ: ИТОГИ КОНФЕРЕНЦИИ «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) ПО СПОРНЫМ ВОПРОСАМ. Нефрология. 2018;22(4):18-39. https://doi.org/10.24884/1561-6274-2018-22-4-18-39

For citation:


H.J. Goodship T., Cook H., Fakhouri F., Fervenza F.C., Fremeaux-Bacchi V., Kavanagh D., Nester C.M., Noris M., Pickering M.C., de Co´rdoba S., Roumenina L.T., Sethi S., J.H. Smith R. ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg). 2018;22(4):18-39. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-4-18-39

Просмотров: 167


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)